Author:
C. George Priya Doss,B. Rajith,Chakraborty Chiranjib,N. NagaSundaram,Ali Shabana Kouser,Zhu Hailong
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127–137 (2001).
2. Arteaga, C. L. Overview of epidermal growth factor receptorbiology and its role as a therapeutic target in human neoplasia. Semin Oncol 29, 3–9 (2002).
3. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129–2139 (2004).
4. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101, 13306–13311 (2004).
5. Wakeling, A. E. et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62, 5749–5754 (2002).
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献